A Daily Network publication
Explore the network
Private Credit Daily
The Daily Read on Private Credit
Sunday, October 4, 2026The Morning Brief →Sign in
XPHSPDRINDEX

SPDR S&P Pharmaceuticals ETF

$63.64-0.22% vs prior close
477452-WK

Price through Oct 2 · Flows through Oct 1. Figures use the latest available records, not a live quote. Fund details retrieved Oct 3. Holdings snapshot retrieved Oct 3.

In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI").

Price & daily flows
68.360.753.163.64DAILY NET FLOWOct 2Feb 2Jun 2Oct 2

SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET +$219M OVER THIS RANGE

The desk’s read

Money is leaving — −$39M in net outflows over the past month, about 7.7% of the fund's asset base, while the price has returned +13.6% so far this year. At 0.35% a year it is not the cheapest way in — AVIE has a reported fee of 0.25%.

COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH

$510Massets under management
0.35%expense ratio · $35 per $10,000 a year
−$39Mnet flow, trailing month
183Kavg daily volume, 30 days
41holdings · US-domiciled
2006listed June 19, 2006 · beta 0.77
The book at a glance
AMLX-1.0%MBX+3.5%OMER+0.8%DFTX-0.5%CORT+1.9%AMRX+1.1%ETON+6.5%PRGO+1.7%ELVN+1.6%EWTX+2.3%MANE-0.4%LGND+0.1%MRK+0.3%TARS-3.3%NUVB-7.6%HRMY+0.2%VTRS+0.8%BMY-0.5%PFE-1.1%PCRX+0.8%MAZE-0.8%JNJ-1.0%RPRX-0.8%XERS-1.8%TRVI-1.9%AMPH+0.3%JAZZ+1.1%OGN+0.1%LLY-0.6%PAHC+3.8%ELAN+1.7%SUPN+0.5%INDV+0.9%PBH+1.1%INVA-0.2%ANIP-1.1%ZTS+0.9%HROW-0.4%OCUL-4.5%NKTR-7.3%

CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS

HoldingsDownload CSV
#HoldingWeightPriceDay52-wk
1AMLXAMYLYX PHARMACEUTICALS2.04%$27.79-1.0%
2MBXMBX Biosciences2.72%$58.51+3.5%
3OMEROMEROS1.42%$18.61+0.8%
4DFTXDefinium Therapeutics3.09%$37.40-0.5%
5CORTCORCEPT THERAPEUTICS1.70%$116.23+1.9%
6AMRXAMNEAL PHARMACEUTICALS1.72%$20.30+1.1%
7ETONETON PHARMACEUTICALS1.30%$55.36+6.5%
8PRGOPERRIGO CO1.42%$14.26+1.7%
9ELVNENLIVEN THERAPEUTICS2.09%$46.97+1.6%
10EWTXEDGEWISE THERAPEUTICS1.88%$41.40+2.3%
11MANEVERADERMICS INC2.02%$116.76-0.4%
12LGNDLIGAND PHARMACEUTICALS1.94%$302.96+0.1%
13MRKMERCK & CO1.65%$144.30+0.3%
14TARSTARSUS PHARMACEUTICALS1.57%$73.00-3.3%
15NUVBNUVATION BIO1.89%$5.14-7.6%

The full book, free with one sign-in.

Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.

Sign in to see all 41
Sector weights
Healthcare100%
Health Technology99.68%
Other0.33%
Mutual fund0.32%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Country weights
United States99.6%
Ireland9.31%
Singapore0.4%
Cayman Islands0.39%
PORTFOLIO COMPOSITION, LATEST DISCLOSURE
Performance
1 week-3.7%
1 month-10.4%
3 months-5.2%
6 months+16.3%
YTD+13.6%
1 year+29.9%
3 years—

PRICE RETURN, DISTRIBUTIONS NOT REINVESTED

Net flows
1 week−$16M
1 month−$39M
3 months+$105M
YTD+$249M
1 year+$256M

CREATION/REDEMPTION DOLLARS, DAILY RECORDS

Monthly net flows
NovDecJanFebMarAprMayJunJulAugSepOct
DAILY CREATION/REDEMPTION RECORDS, TRAILING TWELVE MONTHS
The risk read
22%realized volatility, 30 days (annualized)
23%realized volatility, 1 year
-14.1%deepest fall from a peak, 1 year
-14.1%latest close versus that peak

The top holding is 3.1% of the book; the top ten carry 22%. Spread across 66+ names, it behaves like roughly 60 equally-weighted positions.

VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK

Options tape
1calls · latest snapshot
—puts · latest snapshot
—put/call ratio
256Kshares traded
Most-traded holdings, options premiumBullishBearish
LLY ELI LILLY$23M$27M
PFE PFIZER$5M$5M
JNJ JOHNSON & JOHNSON$3M$4M
LQDA LIQUIDIA$3M$3M
MRK MERCK & CO$2M$2M

TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES

The case against XPH

Due diligence cuts both ways. These funds sit on the same shelf and beat XPH on at least one dimension that matters — the fee, the asset base, or where the money is going.

FundFeeAssetsFlow, 1MThe case
SPDW State Street SPDR Portfolio Developed World ex-US ETF0.03%$41.5B+$286M-32bp on fee · 81× the assets · +$286M in over the monthHead-to-head
SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF0.03%$18.2B+$199M-32bp on fee · 36× the assets · +$199M in over the monthHead-to-head
IDEV iShares Core MSCI International Developed Markets ETF0.04%$32.9B+$497M-31bp on fee · 64× the assets · +$497M in over the monthHead-to-head
IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF0.04%$23.7B+$575M-31bp on fee · 46× the assets · +$575M in over the monthHead-to-head
IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF0.04%$18.6B+$412M-31bp on fee · 36× the assets · +$412M in over the monthHead-to-head
Sign in to save this to The RecordA timestamped copy for the file — documentation, not advice.
InstrumentsHarvest substitutesTrade cost at $1MClient tearsheetStress this fund
Every weekday · 6:30 a.m. ET

The Morning Brief

The latest from Private Credit Daily, in your inbox every weekday. Free.